Abstract:SummaryAimsDaphnetin, a coumarin derivative extracted from Daphne odora var. marginata, has been reported to have antiinflammatory and immunosuppressive properties. Our previous study indicated that it was able to remarkably suppress the neuroinflammation and suggested its potential application in treating neuroinflammatory diseases. Multiple sclerosis (MS), a Th cell‐mediated autoimmune disease, is the most common inflammatory demyelinating disease of the central nervous system (CNS). We examined whether daphnetin treatment can protect mice against experimental autoimmune encephalomyelitis (EAE), an animal model for MS.MethodsTo assess the effect of daphnetin in neuroinflammatory diseases, the EAE mice were established and treated with daphnetin at 8 mg/kg for 28 days. The severity of neuroinflammation and demyelination in the spinal cords was examined histopathologically. Infiltration of CD4+ T cells into the CNS was assessed by immunohistochemistry, and the cytokine production was determined by ELISA. Meanwhile, the effect of daphnetin on the activity of dendritic cells (DCs) was evaluated, as assessed by DCs’ capability to express surface markers, secrete cytokines, and activate naïve CD4+ T cells. Furthermore, we explored the molecular mechanisms whereby DAPH regulated DCs’ activity and thereby CD4+ T cell responses.ResultsThe administration of daphnetin markedly alleviated the clinical symptoms of EAE and reduced the CNS inflammation and demyelination in experimental mice. Th1 and Th17 cell responses were profoundly repressed in daphnetin‐treated EAE mice. Mechanistically, daphnetin treatment significantly repressed the activation, maturation, and antigen‐presenting capability of DCs. NF‐κB signaling was significantly reduced in daphnetin‐treated DCs, along with a concomitant induction of heme oxygenase‐1, a negative regulator of inflammatory signaling.ConclusionsOur findings for the first time demonstrate the property of daphnetin in regulating DCs’ function and subsequently Th development. Given the low or absent toxicity associated with daphnetin, our data may suggest a novel safe and effective approach to control autoimmune neuroinflammation.

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

Role of DAF in Protecting Against T-Cell Autoreactivity That Leads to Experimental Autoimmune Uveitis

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

Manipulation of Qa‐1‐restricted CD8 Suppressor Cell Activity in Experimental Autoimmune Encephalomyelitis

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

Dendritic Cells Exposed in Vitro to TGF-beta1 Ameliorate Experimental Autoimmune Myasthenia Gravis

Soluble MOG35-55/I-Ab Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells

TGFβ1 Transduction Enhances Immunomodulatory Capacity of Neural Stem Cells in Experimental Autoimmune Encephalomyelitis

Therapeutic Potential Of Ifn-Gamma-Modified Dendritic Cells In Acute And Chronic Experimental Allergic Encephalomyelitis

Bone Marrow-Derived Dendritic Cells from Experimental Allergic Encephalomyelitis Induce Immune Tolerance to EAE in Lewis Rats.

Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration

Therapeutic potential of IFN- -modified dendritic cells in acute and chronic experimental allergic encephalomyelitis

Daphnetin Alleviates Experimental Autoimmune Encephalomyelitis Via Regulating Dendritic Cell Activity

[Anti-Oxidative Effects of Dexamethasone on Mice with Experimental Autoimmune Encephalomyelitis].

Interferon-Gamma-Modified Dendritic Cells Suppress B Cell Function and Ameliorate the Development of Experimental Autoimmune Myasthenia Gravis

Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

TGF-β1 Inhibits Protracted-relapsing Experimental Autoimmune Encephalomyelitis by Activating Dendritic Cells

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells

An Ανβ3 Integrin-Binding Peptide Ameliorates Symptoms of Chronic Progressive Experimental Autoimmune Encephalomyelitis by Alleviating Neuroinflammatory Responses in Mice.

In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis.